Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

K. Ray, Kausik; Scott Wright, R.; Kallend, David; Köenig, Wolfgang; A. Leiter, Lawrence; J. Raal, Frederick; A. Bisch, Jenna; Richardson, Tara; Jaros, Mark; Wijngaard, Peter; J.P. Kastelein, John

doi:10.1056/nejmoa1912387

Public

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Published in New England Journal of Medicine • Mar 18, 2020

Authors:

Kausik K. Ray

R. Scott Wright

David Kallend

Abstract

BACKGROUND: Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing. METHODS: We enrolled patients with atherosclerot...

Subject

Ldl cholesterol

Phase (matter)

Cholesterol

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!